Summary

The cardiovascular (CV) safety of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus has been supported by a pooled comprehensive analysis of prospectively adjudicated CV events in Phase 3 studies. CV benefit with linagliptin is being tested prospectively in the CAROLINA study [NCT01243424] against glimepiride and in the CARMELINA study [NCT01897532] against placebo. The pooled analysis included 9459 patients from 19 United States or multinational, multicenter, double-blind, parallel-group studies.